Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert (FAI)
A Phase III, Multi-National, Multi-Center, Randomized, Masked, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal Insert in Subjects With Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye
Sponsor: EyePoint Pharmaceuticals, Inc.
Listed as NCT01694186, this PHASE3 trial focuses on Non-Infectious Uveitis and remains completed. Sponsored by EyePoint Pharmaceuticals, Inc., it has been updated 15 times since 2013, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
15 versions recorded-
Mar 2026 — Present [monthly]
Completed PHASE3
-
Dec 2025 — Mar 2026 [monthly]
Completed PHASE3
-
Sep 2025 — Dec 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
▶ Show 10 earlier versions
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE3
-
May 2021 — Dec 2022 [monthly]
Completed PHASE3
-
Jan 2021 — May 2021 [monthly]
Completed PHASE3
-
May 2020 — Jan 2021 [monthly]
Completed PHASE3
-
Apr 2020 — May 2020 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jun 2018 — Apr 2020 [monthly]
Active Not Recruiting PHASE3
-
May 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Feb 2017 — May 2018 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Aug 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- EyePoint Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .